Umbilical Cord Mesenchymal Stem Cells: Adjuvants for Human Cell Transplantation  by Friedman, Robb et al.
Biology of Blood and Marrow Transplantation 13:1477-1486 (2007)
Q 2007 American Society for Blood and Marrow Transplantation
1083-8791/07/1312-0001$32.00/0
doi:10.1016/j.bbmt.2007.08.048Umbilical Cord Mesenchymal Stem Cells: Adjuvants
for Human Cell Transplantation
Robb Friedman,* Monica Betancur,* Laurent Boissel, Hande Tuncer, Curtis Cetrulo, Hans Klingemann
Tufts-New England Medical Center, Molecular Oncology Research Institute, Boston, Massachusetts
*Both authors contributed equally to the research.
Correspondence and reprint requests: Hans Klingemann, MD, PhD, Tufts-New England Medical Center, 750
Washington Street, Mail 245, Boston, MA 02111; Tel: 617-636-6495; Fax: 617-636-3194 (e-mail: hklingemann@
tufts-nemc.org).
Received July 3, 2007; accepted August 30, 2007
ABSTRACT
The Wharton’s jelly of the umbilical cord is rich in mesenchymal stem cells (UC-MSCs) that fulfill the criteria for
MSCs. Here we describe a novel, simple method of obtaining and cryopreserving UC-MSCs by extracting the
Wharton’s jelly from a small piece of cord, followed by mincing the tissue and cryopreserving it in autologous
cord plasma to prevent exposure to allogeneic or animal serum. This direct freezing of cord microparticles with-
out previous culture expansion allows the processing and freezing of umbilical cord blood (UCB) and UC-MSCs
from the same individual on the same day on arrival in the laboratory. UC-MSCs produce significant concentra-
tions of hematopoietic growth factors in culture and augment hematopoietic colony formation when co-cultured
with UCB mononuclear cells. Mice undergoing transplantation with limited numbers of human UCB cells or
CD341 selected cells demonstrated augmented engraftment when UC-MSCs were co-transplanted. We also ex-
plored whether UC-MSCs could be further manipulated by transfection with plasmid-based vectors. Electropo-
ration was used to introduce cDNA and mRNA constructs for GFP into the UC-MSCs. Transfection efficiency
was 31% for cDNA and 90% for mRNA. These data show that UC-MSCs represent a reliable, easily accessible,
noncontroversial source of MSCs. They can be prepared and cryopreserved under good manufacturing practices
(GMP) conditions and are able to enhance human hematopoietic engraftment in SCID mice. Considering their
cytokine production and their ability to be easily transfected with plasmid-based vectors, these cells should have
broad applicability in human cell–based therapies.
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Mesenchymal stem cells (MSCs) are being increas-
ingly developed for indications in the growing field of
regenerativemedicine and also for their ability tomod-
ulate the immune response [1,2]. Recent clinical trials
have suggested that bone marrow–derived MSCs
(BM-MSCs) can aid children born with osteogenesis
imperfecta [3], improve cardiac function after myocar-
dial infarction [4], and treat acute graft-versus-host
disease (aGVHD) after bone marrow (BM) transplan-
tation [5,6]. Given that harvesting of BM-MSCs
involves a painful, invasive procedure, alternative sour-
ces of MSCs may prove more useful. Recently, extrac-tion and characterization of MSCs derived from fetal
tissues, such as the placenta and the umbilical cord, as
well as from umbilical cord blood (UCB), have been
described [7-11].
During embryogenesis, cells from the hematopoi-
etic progenitor tissue of the fetus, the aortamesogonad
region, migrate through the developing cord. It is be-
lieved that some of these early cells are trapped there
and contribute to the cellular composition of the
cord [12]. Inside the cord is a jelly-like matrix material
that protects the cord arteries and the vein, initially
described by Thomas Wharton in 1656 (‘‘Wharton’s
jelly’’). Termed umbilical cord MSCs (UC-MSCs),
these cells have many of the same characteristics as1477
1478 R. Friedman et al.BM-MSCs; they adhere to plastic, express characteris-
tic surface markers, and can differentiate into cells
of mesenchymal origin, including bone, cartilage,
adipose tissue, and neuronal cells [13-15]. Reports to
date have focused on obtaining those cells after culture
expansion from a segment of the umbilical cord [14-
16]. However, culture expansion has a disadvantage,
in that the cells cannot be frozen on the same day as
UCB cells arrive in the laboratory, and there is the in-
creased risk of contamination with any culture manip-
ulation. Thus, one objective of this study was to
develop a rapid same-day procedure for preparing
and freezingUC-MSCs that would be suitable for clin-
ical application.
Because previous studies have suggested that co-
transplantation of BM-MSCs with hematopoietic
stem cells can accelerate hematopoietic engraftment
after transplantation [17,18], we hypothesized that
a similar effect could be accomplished when UC-
MSCs were used to support UCB transplantation.
UCB is a viable source of hematopoietic stem cells
for treating hematologic diseases in both children
and adults without amatched donor [19-21]. It has sev-
eral advantages over matched unrelated donor marrow
or peripheral blood stem cell transplantation: UCB
units are more readily available, allow for some HLA
mismatches between patient and donor, and have
a lower incidence of GVHD [22,23]. However, the
currently stored units will only allow transplantation
of\10% of adults with an average weight of 70 kg
when 1 UCB unit is used [24]. Attempts at expanding
UCB ex vivo have yielded mixed results, with mostly
committed progenitors being expanded that are not
responsible for long-term engraftment [25].
Using standard transfection protocols, we also
were able to show that UC-MSCs are amenable to
gene transfection. This may be relevant to further en-
hance hematopoietic and immune cell engraftment
and ex vivo expansion protocols in which UC-MSCs
may be used as feeders.
METHODS
Isolation and Culture
Umbilical cords and cord blood were processed
within 24 hours after vaginal delivery or cesarean
section. The protocol was approved by Tufts-New
England Medical Center Institutional Review Board.
The cords were delivered in a sterilized jar to the lab-
oratory and kept at room temperature if they could not
be prepared immediately. After washing in phosphate-
buffered saline (PBS) to remove any contaminating
blood, the cord was cut into small pieces (0.5-1 cm),
and the vessels were removed to avoid endothelial
cell contamination. The pieces were either minced
and cryopreserved, as described in the Results section,
or placed directly into 6 well plates for culture expan-sion in 20% FBS/RPMI 1640 (Cambrex,Walkersville,
MD) supplemented with antibiotics (penicillin 100 mg/
mL, streptomycin 10 mg/mL, amphotericin B 250 mg/
mL, [all fromGibco, CA] and ciprofloxacin 10 mg/mL,
[Mediatech, Herdon, VA]). Cultures were maintained
at 37C in a humidified atmosphere containing 5%
CO2, with a change of 20% FBS/RPMI 1640 every
3-4 days. When colonies of fibroblast-like cells ap-
peared and the wells reached 80% confluence, the cul-
tures were rinsed with PBS, harvested with 0.05%
trypsin-EDTA (Gibco), and transferred into a 75-
cm2 flask for further expansion. Cell growth also was
tested without FBS, using only RPMI 1640 or
X-Vivo 10 (Cambrex). For cryopreservation of the
UC-MSCs, autologous UC plasma was obtained by
centrifuging aUCB sample at 1700 rpm for 15minutes
at room temperature. Human serum (HS) was ob-
tained from Cambrex. All sera were heat activated.
Human BM-MSCs were isolated from BM aspi-
rates of healthy volunteers, after informed consent
had been obtained. After Ficoll separation, the mono-
nuclear cells (MNCs) were plated at a density of 106
cells/cm2 in 20% FBS/RPMI 1640. The culture ex-
pansion protocol was the same as described for the
UC-MSCs using 20% FBS/RPMI 1640.
UC-MSCs were stained with fluorescein isothio-
cyanate (FITC)-conjugated antibodies against the fol-
lowing surface markers: CD3, CD14, CD19, CD34,
CD45, CD49b, CD80, and HLA-class I (all obtained
from BD Pharmingen, San Diego, CA). Unconjugated
Anti-3G5 and anti-STRO-1 were obtained fromR&D
Systems (Minneapolis,MN) and detected with second-
ary anti-IgG FITC-conjugated antibody from Caltag
(Burlingame, CA). Phycoerythrin (PE)-conjugated
antibodies were used to identify the following surface
markers: CD7, CD29, CD33, CD44, CD73, CD86,
and CD166. PE-Cy5–conjugated antibodies were
used for CD58, CD117, and HLA-DR. Anti-CD40
and anti-CD49d were conjugated with APC (all
antibodies obtained from BD Pharmingen). The PE-
conjugated anti-CD105 was from R&D Systems, and
the anti-CD133 was from Miltenyi (Auburn, CA).
Mouse isotypic antibodies (from BD Pharmingen)
served as controls. Stained cells were analyzed by
flow cytometry with a CyAn flow cytometer (Dako
Colorado, Ft. Collins, CO).
Cytokine Production of UC-MSCs and BM-MSCs
To assess cytokine production by UC-MSCs and
BM-MSCs, 104 cells/well of each cell type were seeded
into 6 well tissue culture plates (BD Biosciences,
Franklin Lakes, NJ) and grown to confluence in 20%
FBS/RPMI 1640 medium for 7 days with no medium
change. The supernatant was removed and new me-
dium was supplied to the wells for 24 hours, after
which the supernatant was collected and sent to Pierce
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enzyme-linked immunosorbent assay (ELISA) for
the following cytokines/growth factors: granulocyte
colony-stimulating factor (G-CSF), granulocyte
macrophage colony-stimulating factor (GM-CSF),
thrombopoietin (TPO), vascular endothelial growth
factor (VEGF), stromal cell derived factor-1 (SDF)-
1b, transforming growth factor (TGF)-a, TGF-b, hu-
man growth factor (HGF), interferon (IFN)-a, IFN-g,
tumor necrosis factor (TNF)-a, leukemia inhibitory
factor (LIF), interleukin (IL)-1a, IL-2, IL-6, IL-7,
IL-8, IL-11, IL-12p40, IL-15, and IL-18. Media
with no MSCs were tested as controls.
Hematopoietic Colony Formation Assay
UC-MSCs were plated at a concentration of 2 
105 cells, grown to confluence in 35-mm culture plates,
and irradiated with 3200 cGy. UCB CD341 cells were
selected using the Miltenyi Biotec MiniMACS system
and suspended at a concentration of 1 103 cells/mL
in MethoCult H4434 (StemCell Technologies, Van-
couver, Canada). The cells were then plated on top
of the UC-MSCs containing culture plates as well as
on plates cultured withoutMSCs, which served as con-
trols. The numbers of CFU-GEMM, BFU-E, and
CFU-GM colonies were counted on day 14.
Co-Transplantation of NOD/SCID Mice with
UCB Cells and UC-MSCs
All experiments and procedures in animals were
performed in compliance with the regulations for ani-
mal experimentation at Tufts-New England Medical
Center. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NOD/
SCID gcnull) mice were purchased from Jackson Lab-
oratories (Bar Harbor, ME) and were maintained in
sterile microisolator cages under specific pathogen-
free conditions and provided with irradiated food.
Four groups of 8 mice each (age 8-10 weeks) were sub-
lethally irradiated with 350 cGy and underwent trans-
plantation with the following cells from the same cord
donor: 106 umbilical cord MNCs alone or together
with 106 UC-MSCs or 104 CD34 selected cells alone
or together with 106 UC-MSCs. Cells were suspended
in 250 mL of PBS and injected slowly into a lateral tail
vein. The mice were sacrificed 6-8 weeks after trans-
plantation. Peripheral blood samples were obtained
by cardiac puncture, and BMwas harvested by flushing
femurs and tibias with PBS. Flow cytometry for the
HLA CD45 was used to document engraftment with
FITC-conjugated antibody to human CD45 (BD
Pharmingen) and PE-conjugated antibody to murine
CD45 (eBioscience, San Diego, CA).
Transfection of UC-MSCs with Plasmid DNA
or mRNA for GFP
DNA electroporation was performed using the
pEGFP-C1 plasmid (Clontech, Mountain View,CA). GFPmRNA was synthesized in vitro from a line-
arized GFP-pXT7 plasmid template (with the pXT7
a gift fromDr S. Sokol), using theT7mMessagemMa-
chine kit (Ambion, Austin, TX) according to the man-
ufacturer’s instructions. UC-MSCs were trypsinized
and resuspended in MEM medium (Gibco, Carlsbad,
CA) at a concentration of 2 106 cells/mL. Electropo-
ration was performed on a Genepulser II (Bio Rad,
Hercules, CA) on 4  105 cells (200 mL) per 4-mm
cuvette using different voltages (150 and 300 V) and
capacitances (150 and 300 mF). DNA (75 mg/mL) or
mRNA (25 mg/mL) was added directly to the cell
suspension and incubated for 2 minutes at room tem-
perature before electroporation. After transfection,
cells were transferred to 6 well plates with 20% FBS/
RPMI and allowed to grow for 40 hours at 37C.
Expression of GFP was analyzed by flow cytometry
of trypsinized cells stained with propidium iodide
(10 mg/mL in PBS) before analysis.
Statistical Analysis
Data are presented as mean6 standard error of the
mean unless otherwise noted. Statistical analyses using
SPSS 11.5 software (SPSS, Chicago, IL) were per-
formed with the Student t test. All p values \.05
were considered statistically significant.
RESULTS
Rapid Preparation of UC-MSCs for
Cryopreservation under GMP Conditions
One objective of this study was to show that UC-
MSCs could be prepared and frozen without previous
culture expansion. To further avoid storage in animal
or human allogeneic serum, we tested whether a small
piece of cord (0.5-1 cm) could be minced and immedi-
ately frozen in autologous cord plasma and stillmaintain
all of the characteristics of fresh and culture-expanded
UC-MSCs. Blood vessels were removed from the
cord section, and the remaining Wharton’s jelly was
cut into 1- to 2-mm3 fragments using sterile scissors.
The tissue particles were further minced and then
mixed with 10 % DMSO and heat-inactivated autolo-
gous cord plasma. The minced pieces were transferred
into a 5-mLVueLife bag (AFC, Gaithersburg, MD) or
cryovials and stored at -80C until further use. To test
whether UC-MSCs can be expanded from the frozen
cord pieces, the thawed, minced microparticles were
placed into 6 well plates in the presence of 5 different
serum conditions (10% or 20% FBS, 10% or 20%HS,
and autologous cord plasma). Serum was sup-
plemented with either X-Vivo10 or RPMI 1640. The
viability of thawed UC-MSCs was consistently
.90% by trypan blue staining. The medium was
changed every 3-4 days. UC-MSCs plated with FBS
(10% or 20%) became readily adherent and displayed
the fastest growth kinetics (Figure 1A). FBS at 20%
1480 R. Friedman et al.Figure 1. A, Expansion of UC-MSCs in various culture media. Fresh cord pieces were minced and those particles were
cryopreserved in 10%DMSOand autologous cord plasma to avoid exposure of UC-MSCs to allogeneicmedia. After thaw-
ing, UC-MSCs were expanded in 20% FBS, 10% FBS, 20%HS, 10%HS, or autologous cord plasma. The number of ex-
panded cells is plotted on the y-axis. All sera were heat-inactivated and supplemented with either RPMI 1640 or X-Vivo10.
FBS at 20% resulted in the best expansion. No difference was seen for RPMI 1640 or X-Vivo10 as base media. Results from
1 of 3 representative experiments are presented. B,Microscopic view ofUC-MSCs cultured in either 20%FBS/RPMI 1640
or 20% HS/RPMI 1640 appearance (original magnification  40). In HS, the MSCs tend to form clumps, with less UC-
MSCs becoming adherent. Spreading of the clumps can be observed when plucked and replated in 20% FBS.promoted growth significantly better than FBS at
10%. Significantly slower growth was observed in cells
cultured in HS. The cell morphology also differed, in
that UC-MSCs in HS grew in clumps with fewer cells
spreading out on plastic (Figure 1B). Cord plasma
did not support the expansion of UC-MSCs. No
significant differences were observed when either X-
Vivo10 or RPMI 1640 was used as the base medium.
Notably, neither X-Vivo10 nor RPMI 1640 by itself
supported the expansion of UC-MSCs in culture.
There was also no difference as to whether cells were
initially cryopreserved in either VueLife bags or cyro-
vials (data not shown). The doubling time was calcu-
lated for UC-MSCs derived from 6 UC and
expanded in FBS 20%/RPMI 1640. The mean dou-
bling time was 2.26 days (range, 1.6-3.3) for up to 7
passages (data not shown).
To determine whether there is an area of the cord
that is particularly rich in UC-MSCs, representative
samples from different areas of the entire length ofthe cord were obtained, and cells were cultured for 7,
14, and 21 days. No significant differences were noted
with respect to expansion kinetics among UC-MSCs
obtained from the areas adjacent to the placenta, mid-
dle and distal, or adjacent to the umbilicus (data not
shown).
Antigen Expression on UC-MSCs
Table 1 compares the surface antigen expression of
UC-MSCs and BM-MSCs. UC-MSCs cultured in
20% FBS/RPMI expressed the following surface anti-
gens to various extents: CD29, CD44, CD49b, CD58,
CD73, CD105, CD166, and HLA-ABC. UC-MSCs
stained negative for the following surface antigens:
CD3, CD7, CD14, CD19, CD33, CD34, CD40,
CD45, CD49d, CD80, CD86, CD117, CD133,
3G5, STRO-1, and HLA-DR. Cells cultured in 10%
or 20% HS instead of FBS demonstrated the same
antigen expression profile (data not shown).
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Table 2 compares the concentrations of cytokines
produced by UC-MSCs and BM-MSCs. UC-MSCs
secrete significantly higher concentrations of G-CSF,
GM-CSF, HGF, LIF, IL-1a, IL-6, IL-8, and IL-11
compared with BM-MSCs, whereas BM-MSCs
produce more VEGF and SDF-1b than UC-MSCs.
Production of IL-2, IL-7, IL-12p40, IL-15, IL-18,
IFN-a, IFN-g, and TNF-a was negligible for both
UC-MSCs and BM-MSCs.
UC-MSCs Increase Hematopoietic Progenitor
Cell Proliferation
CD341 cells from human UCB were suspended
in Methocult and either plated on a monolayer of
irradiated (3200 cGy) UC-MSCs grown to conflu-
ence or plated in a culture dish without a UC-MSC
monolayer (Methocult only). Hematopoietic colony
formation was assessed after 14 days of incubation.
Significantly more CFU-GM colonies (184 6 34 vs
94 6 16; P 5 .017), but not BFU-E (126 6 11 vs.
70 6 20; P 5 .06) or CFU-GEMM (35 6 4 vs
15 6 3; P 5 .6) colonies were generated in the pres-
ence of the UC-MSC monolayer than without after 2
weeks of culture.
Table 1. Percentages of UC-MSCs and BM-MSCs expressing surface
markers as determined by flow cytometry
Marker UC-MSC BM-MSC
CD3 - -
CD7 - -
CD14 - -
CD19 - -
CD29 111 111
CD33 - -
CD34 - -
CD40 - -
CD44 111 111
CD45 - -
CD49b 11 -
CD49d - -
CD58 111 111
CD73 111 1111
CD80 - -
CD86 - -
CD105 1111 1111
CD117 - -
CD133 - -
CD166 111 111
HLA ABC 1 11
HLA DR - -
3G5 - -
STRO-1 - -
The expression levels are as follows: 1 5 0%-25%; 11 5 26%-
50%; 111 5 51%-75%; 1111 5 76%-100%.
The data present the average of 4 independent experiments.
Co-Transplantation of NOD/SCID gcnull Mice
with UCB and UC-MSCs
Irradiated NOD/SCID gcnull mice were injected
either with UCB cells (unfractionated MNCs) or se-
lected CD341 cells either with and without 106 UC-
MSCs, extracted from the same UC as the UCB. BM
and peripheral blood were harvested 6-8 weeks after
transplantation and analyzed for human cell engraft-
ment based on the number of human CD451 cells
found. As shown in Figure 2, mice undergoing trans-
plantation with UCB cells alone demonstrated 1.9%
human CD451 cell engraftment in the BM and 5.9%
human CD451 cells in peripheral blood, whereas
mice receiving the same number of UCB cells and
106 UC-MSCs had an average of 6.7% human
CD451 cells engrafted in the BM (P 5 .017) and
38.4% human CD451 cells engrafted in the peripheral
blood (P 5 .001). Similar results were observed when
CD341 selected cells were transplanted instead of
unfractionated MNCs. CD341 cells alone resulted in
4.5% of human cells in the BM and 2.7% in peripheral
blood, whereas co-transplantation with UC-MSCs re-
sulted in 10.1% human cells in BM and 2.1% in blood.
The difference for BM was significant (P 5 .001).
In some mice, human MSCs, as evidenced by the
expression of CD1051, were found in BM of mice
co-transplanted with UC-MSCs but not in mice trans-
planted with UCB alone. This was not seen consis-
tently in all mice that underwent transplantation,
however. Furthermore, some mice that were co-trans-
planted with UCB and UC-MSCs showed a positive
Table 2. Cytokine production by FBS, UC-MSCs, and BM-UCMs, as
measured by ELISA
FBS UC-MSCs BM-MSCs P
GCSF \1.6 1845.7 ± 881.0 1.1 ± 0.3 .007
GM-CSF \11.7 118.9 ± 19.6 8.3 ± 3.3 .023
TPO 83.2 165.7 ± 4.5 160.2 ± 2.6 NS
VEGF 31.5 151.4 ± 4.7 2762.1 ± 99.0 \.001
SDF1b \6.3 408.9 ± 53.1 2348.2 ± 177.6 \.001
TGFb 7267.5 11079.9 ± 584.6 9493.8 ± 30.8 NS
HGF 1.0 12596.8 ± 7101.2 402.6 ± 203 \.001
LIF 17.1 169.2 ± 34.9 58.5 ± 2.5 .001
TNF-a \4.7 3.4 ± 1.1 4.9 ± 1.3 NS
IFN-a 0.1 4.0 ± 0.5 2.4 ± 0.2 NS
IFN-g \0.4 1.9 ± 0.3 0.6 ± 0.1 NS
IL-1a \0.4 12.5 ± 3.87 0.5 ± 0.1 .001
IL-2 \0.4 \0.4 \0.4 NS
IL-6 \0.4 1571.0 ± 617.2 704.0 ± 51.5 .002
IL-7 0.9 7.72 ± 1.0 8.85 ± 0.8 NS
IL-8 \0.4 10765.3 ± 5382.6 216.9 ± 26.6 \.001
IL-11 \2 1474.4 ± 625.3 71.8 ± 0.7 .001
IL-12 \0.4 \0.4 \0.4 NS
IL-15 0.7 5.1 ± 0.3 5.0 ± 0.1 NS
IL-18 0.8 20.8 ± 1.2 17.9 ± 0.1 NS
All values represent the mean of 4 experiments 6 standard error of
the mean, in pg/mL of cytokine.
NS indicates not significant.
1482 R. Friedman et al.38.4%
6.7%1.9% 5.9%
0
10
20
30
40
50
60
MNC MNC + UC-MSC MNC MNC + UC-MSC
Marrow Peripheral Blood
%
 
h
u
m
a
n
 
C
D
4
5
+
 
c
e
l
l
s
p = 0.02
p = 0.001
4.5%
10.1%
2.7% 2.1%
0
2
4
6
8
10
12
14
16
18
20
CD 34+ cells CD 34+ cells +
UC-MSC
CD 34+ cells CD 34+ cells +
UC-MSC
Marrow Peripheral Blood
%
 
h
u
m
a
n
 
C
D
4
5
+
 
c
e
l
l
s
p = 0.03
p = 0.57
A
B
Figure 2. Engraftment of human BM cells in NOD/SCID mice. The mice underwent transplantation (intravenous injec-
tion) either with UCB cells at 106 alone or together with 106 UC-MSCs (A) or with CD34-enriched UCB cells at 104 alone
or together with 106 UC-MSCs (B). Human cell engraftment was assessed at 6-8 weeks according to the human CD45
marker. Co-transplanted UC-MSCs augmented engraftment for transplantation of unfractionated UCB cells as well as
CD34 selected hematopoietic precursors.signal for CD41 in blood, which identifies the GPIIa/
IIIb protein on platelets (results not shown).
Transfection of UC-MSCs with cDNA and mRNA
UC-MSCs have potentially broad clinical appli-
cability, and it is relevant to show that they can be
manipulated to express certain surface molecules in-
volved in homing to target organs to produce chemo-
kines and cytokines to support hematopoiesis or to
mediate antitumor effects. We compared transfection
of UC-MSCs with a plasmid-based cDNA construct
and transfection with mRNA. Results presented in
Figure 3 show that UC-MSC can be readily trans-
fected with the GFP reporter gene. The transfection
efficiency for cDNA was 30.9% and that for mRNA
was 89.8%. Significant expression of GFP after mRNA
transfection was maintained for at least 4 days.
DISCUSSION
MSCs can be isolated from multiple sources and
have different properties depending on the tissue ori-gin and degree of differentiation. MSCs derived from
human BM are in clinical trials to treat Crohn’s dis-
ease, to treat GVHD after stem cell transplantation
(SCT), or to support bone and cartilage regeneration.
These cells are known to play a vital role in the hema-
topoietic niche and serve as structural elements and
nurse cells for hematopoietic cells [26]. Based on these
observations, BM-MSCs seem to be ideal candidates
to support hematopoietic cell engraftment after stem
cell transplantation, especially given the low hemato-
poietic stem cell dose often found in UCB, which fre-
quently is the cause of delayed engraftment or graft
failure in transplant recipients. As shown here, UC-
MSCs are readily extracted from the Wharton’s jelly
of the UC and thus represent a readily accessible abun-
dant source of MSCs to aid in UCB transplantation.
They have been shown to differentiate into other tis-
sues of mesenchymal origin, such as adipocytes, carti-
lage, bone, and nerve cells [14-16].
Our method of cryopreserving UC-MSCs from
the fresh cord early after delivery with minimal ma-
nipulation and cryopreservation in autologous cord
Umbilical Cord MSC to Support Cell Transplantation 1483R13
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Figure 3. Transfection of UC-MSCs with the GFP reporter gene. Adherent cells were transfected using the BioRad
electroporator with either cDNAormRNA at different voltages and capacitance, as indicated. mRNA showed higher trans-
fection efficiency than cDNA, with expression of the GFP gene maintained for several days.plasma avoids exposure of UC-MSCs to either animal
serum or allogeneic HS. Both serum preparations are
known to alter the gene profile and antigen expres-
sion of MSCs [27,28]. In addition, FBS or allogeneic
HS potentially could be contaminated with viruses or
prions, and preserving UC tissue in autologous cord
plasma avoids those risks. Mincing and freezing the
cord tissue in autologous cord serum is of practical
importance from a UCB banking perspective, because
this method avoids previous culture expansion of
UC-MSCs. It allows for freezing of the UC-MSCs
at the same time as the UCB arrives, and both cell
types can be stored in the same dual-chamber bag.This facilitates the use of autologous UC-MSCs for
any medical indication (beyond transplantation) at
a later point. Our results also confirm that large num-
bers of UC-MSCs can be expanded in culture from
a small piece of cord that has been finely minced
and that the microparticles can be cryopreserved on
arrival in the laboratory. When preparing the cord,
special care was taken not to collect the perivascular
cells in the cord (pericytes), which have different
characteristics despite being MSCs [9]. Our cells
were consistently negative for the 3G5 surface anti-
gen, suggesting that our preparations were free of
pericytes.
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MSCs after thawing is 20% FBS in either RPMI
1640 or X-Vivo10. Inferior results were obtained
with 10% FBS or HS, even at 20%. The cells did not
expand in autologous cord plasma at all. The require-
ment of FBS for optimum expansion is not unique for
UC-MSCs; human BM-MSCs also grow best in FBS
[29]. Consequently, even the BM-MSCs used in cur-
rent clinical trials were expanded in FBS. Recent data
suggest though that serum obtained from platelet-
rich plasma support MSC expansion [30]. Our results
further demonstrate that UC-MSCs grow well in X-
Vivo10 when used to supplement FBS. A drug master
file exists with the FDA for X-Vivo10 for use in clinical
trials.
UCB is a viable source of hematopoietic stem cells
for transplantation in both children and adults under-
going treatment for hematologic malignancies and
some nonmalignant disorders. However, the utility
of UCB transplantation in adults is limited by the total
cell dose contained in a single stored unit of UCB, and
attempts of ex vivo expansion of UCB have shown that
largely committed hematopoietic progenitors expand
that are unable to provide long-term engraftment
[25]. Transplantation of 2 or more umbilical cords
has been found to shorten engraftment after transplan-
tation to some degree [31]; however, questions remain
about the long-term effects of transplanting multiple
immune systems, in addition to the increased procure-
ment costs.
Co-transplantation of hematopoietic stem cells
and MSCs obtained from BM has demonstrated en-
hanced engraftment in NOD/SCID mice, especially
when hematopoietic stem cells were given at subopti-
mal doses [16,17,32,33]. These encouraging results
led to human trials that demonstrated that infusion
of MSC in adults is safe and well tolerated; however,
none of these trials demonstrated a conclusive engraft-
ment advantage, likely because the number of hemato-
poietic stem cells transplanted from BM was already
sufficiently high to allow timely engraftment [34,35].
We have shown that in a NOD/SCID mouse model,
human UC-MSCs, when co-injected with human
UCB cells, can accelerate human hematopoietic stem
cell recovery when limited numbers of UCB cells or
CD34 cells are injected. This improved engraftment
may be explained by the ability of UC-MSCs to pro-
vide a matrix or stroma for engrafting stem cells.
Although studies by Noort et al [17] indicated that
intravenously administered MSCs are initially ‘‘trap-
ped’’ in the lung and then possibly recirculate, our
data show that small numbers of human UC-MSCs
can be found in the BM, as demonstrated by the pres-
ence of human CD1051 cells in the marrow of some
mice (data not shown). This assessment was done 6
weeks after infusion of UC-MSCs, which may have
been too early to reflect a more robust engraftmentof MSC. Muguruma et al [26] reported that significant
human MSC engraftment was detected in the marrow
of SCID mice at 6 months. We show here that UC-
MSCs produce hematopoietic growth factors and the
augmented human cell engraftment seen in SCID
mice also could be facilitated by the production of
those cytokines, released by co-injected UC-MSCs
(eg, GM-CSF, G-CSF, IL-1, IL-8, IL-11). Of poten-
tial clinical interest is our preliminary observation of
human platelets in the BM of SCID mice when they
were co-transplanted with UC-MSCs.
The UCB cells and UC-MSCs in this study were
injected intravenously, and it is possible that injection
of both cell types directly into the BM cavity could ac-
celerate engraftment to an even greater extent, because
cells would not have to pass through the lung and other
organs. Intra-BM transplantation has been explored in
the murine system [36,37].
Another clinical indication for UC-MSCs is their
use as a feeder layer to expand hematopoietic stem
cells, immune cells, or any other cell type. Studies us-
ing BM-MSCs have suggested that expansion of UCB
cells was superior when they were co-cultured with
MSCs [33]. We have shown that co-culture of UCB
cells with UC-MSCs resulted in significantly more
hematopoietic colonies than without UC-MSCs. We
also have recently shown that UCB natural killer cells
are effectively expanded when cultured with cytokines
on a feeder layer of UC-MSCs [38].
To further developUC-MSCs as ‘‘custom’’ feeders
for expansion of human cells, we exploited their ability
to be transfected with target genes, using GFP as
a model gene. To avoid a retrovirus-based construct,
we used a plasmid-based vector and electoporation.
Cultured adherent UC-MSCs displayed excellent
transfection efficiency both for cDNA andmRNA vec-
tors, with expression of the marker gene maintained
for at least 2 days. Not unexpectedly, transfection effi-
ciency was greater with mRNA, because the trans-
fected construct does not have to enter the nucleus.
mRNA is not integrated into the genome and usually
is degraded over time, simplifying the regulatory
requirements. However, a disadvantage could be the
time-limited expression of the mRNA. In addition to
using such engineered UC-MSCs as feeder layers,
they also could be used as carriers for anti-inflamma-
tory or tumoricidal compounds, because MSCs have
been shown to home to sites of inflammation and ma-
lignant histology [39-41]. Their easy ‘‘transfectability’’
and low allogeneic potential because of low HLA class
I expression could make these cells ideal candidates for
this indication.
In conclusion, UC-MSCs hold significant promise
in the emerging field of regenerative medicine and cel-
lular therapy. We have described a novel method of
obtaining UC-MSCs for rapid cryopreservation and
showed that these cells can support engraftment of
Umbilical Cord MSC to Support Cell Transplantation 1485a limited number of human UCB hematopoietic stem
cells in a NOD/SCID transplant model. Furthermore,
we have shown that UC-MSCs can be readily trans-
fected with a plasmid-based vector through electropo-
ration. These characteristics make UC-MSC ideal
platform candidates for a broad range of cell-based
therapies.
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